NRP1 and cancer: In some studies, Nrp1-binding peptides or knockdown of Nrp1 by siRNA inhibited cancer cell growth and increased the sensitivity of the cells to chemotherapeutic agents (e.g., 5-FU, paclitaxel, and cisplatin) [61].